Free Press Release

FaceBook Page Twitter Feed
You are here: Home > Exclusive News > Asia Pacific insulin market is expected to reach more than USD 10 Billion by 2018

Asia Pacific insulin market is expected to reach more than USD 10 Billion by 2018

Posted Sep 18, 2014 by kenresearch12
The report entails the segment wise market share analysis and company profiles of major players in the insulin market in China.

FOR IMMEDIATE RELEASE (Press Release) Sep 18, 2014 -- • Future Growth of the insulin market will be led by greater consumption of the long acting insulin
• Market leaders are anticipated to maintain focus on expanding R&D facilities and distribution network in emerging markets of China and India

Ken Research announced its latest publication on “Asia Pacific Insulin Market Review to 2018” which provides a comprehensive analysis of major countries and types of insulin consumed in the region. The report covers various aspects such as market size of Asia Pacific insulin market, segmentation on the basis of geographies (China, India and Japan) and future outlook of the market. The report is useful for insulin manufacturers and distributors, as well as new players venturing in the market.

Diabetes is spreading more rapidly in Asia Pacific than any other region in the world. It is a perceived notion that unlike the western countries where diabetes affects older people, in Asia Pacific, the disease is disproportionately high in young to middle-aged adults. Insulin, the basis of diabetes treatment has witnessed a surge in demand in the past decade. Factors such as growing diabetic population, increasing expenditure on healthcare both by the consumers and the government, expanding distribution network and high scope in developing economies such as China and India poses to be potential drivers for the insulin market in Asia Pacific region. The market registered a CAGR of 13.9% during 2008-2013.

According to the research report, the Asia Pacific insulin market will grow at an impressive CAGR, thereby exceeding USD 10 billion by 2018, largely due to increasing incidence of diabetes and rising healthcare expenditure both by the government and the consumers.

“Although lack of diabetes care awareness and low affordability will hinder the growth of the insulin market in the Asia Pacific, rising disposable income of the population and diagnosis of diabetes will cater to increasing consumption of insulin in the region”, according to the Research Associate, Ken Research.

Key Topics Covered in the Report:
- Asia Pacific Insulin Market Size by Revenue
- Market Segmentation by Geographies (China, India, Japan)
- Trends, Growth Drivers and Issues
- Country wise market size and segmentation
- Competition and Market Share
- Future Outlook
- Macro Economic Parameters
Key Products Mentioned in the Report
Human Insulin
Analog Insulin
Premix Insulin
Rapid Acting Insulin
Long Acting Insulin

Companies Covered in the Report
Novo Nordisk
Eli Lilly and Company
Sanofi Aventis
BJ Ganli Pharmaceuticals
Tonghua Dongbao

Browse and Download Report Here-

Related Reports:
The US Diabetic Devices Industry Outlook to 2018 - Growth to be Led by Next Generation Technology
India Diabetes Industry Research and Forecasts to FY'2016 - Shift towards Modern Insulin Delivery Devices
The US Anti Cancer Drug Market Outlook to 2018

Ken Research
Information Department
[email protected]
-- EOF ---
Contact Email :
Issued By : Ken Research
Website : Market Research Company
Phone : +91 1147017199
Business Address : 109-110, NDM II, Netaji Subhash Place, Pitampura,
New Delhi, Delhi, India - 110034
Country : India
Categories : Health, Reports, Research
Tags : Asia Pacific Insulin Market, Asia Insulin Industry, Insulin Market, Insulin Sector, Insulin Industry, Diabetes Insulin China, India Insulin Marke, Type 1 Insulin Market
Last Updated : Sep 18, 2014

New Press News

blog comments powered by Disqus
Popular TagsMore